X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the collaboration, Shasqi will apply its novel tumor-targeted Click Activated Protodrugs Against Cancer (CAPAC®) platform to the development of new cancer therapies and research on Shasqi's intratumorally injected biopolymer, SQ3370 (SQL70).
Lead Product(s): SQL70,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: SQ3370
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration October 04, 2023
Details:
Through the collaboration, Shasqi will apply its novel tumor-targeted CAPAC® platform to the development of new cancer therapies and will focus on Shasqi’s SQ3370, consisting of SQL70, a protodrug-activating biopolymer, and SQP33, a protodrug of Doxorubicin.
Lead Product(s): SQL70,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: SQ3370
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Enterprise Innovation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 01, 2023
Details:
SQ3370 is the first click chemistry-based treatment to be tested in humans, utilizes Shasqi’s proprietary CAPAC platform, an approach that activates cancer drugs at a tumor with decreased systemic toxicity.
Lead Product(s): SQP33,SQL70
Therapeutic Area: Oncology Product Name: SQ3370
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2022
Details:
The funds will be used to advance the Phase 1/2 clinical study of SQ3370 for the treatment of injectable, advanced solid tumors, and will enable Shasqi to expand its click chemistry platform to create therapeutics that do not require intratumoral injections.
Lead Product(s): SQP33,SQL70
Therapeutic Area: Oncology Product Name: SQ3370
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Arcus Biosciences
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing November 11, 2021
Details:
Presentations include updated data from Phase 1 study of SQ3370 in patients with advanced solid tumors and nonclinical data on SQ3370 combined with cancer immunotherapies. SQ3370 utilizes Shasqi’s proprietary CAPAC platfor that activates cancer drugs with less toxicity.
Lead Product(s): SQP33,SQL70
Therapeutic Area: Oncology Product Name: SQ3370
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2021
Details:
The grant will support immune biomarker analysis of patient samples from Shasqi’s Phase 1 clinical trial of lead candidate SQ3370 as well as manufacturing process development.
Lead Product(s): SQP33,SQL70
Therapeutic Area: Oncology Product Name: SQ3370
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Funding April 27, 2021
Details:
SQ3370 is a novel investigational product that activates a non-toxic protodrug into a powerful chemotherapy agent, doxorubicin, precisely at a pre-injected tumor.
Lead Product(s): SQP33,SQL70
Therapeutic Area: Oncology Product Name: SQ3370
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2020
Details:
The study, titled “SQ3370, a Local Activation Therapy of Cytotoxic Agents, Produces Sustained Responses in Target and Distal Lesions via Immune Activation,” was presented in a poster with audio at the American Association for Cancer Research Virtual Annual Meeting II.
Lead Product(s): SQL70,SQP33
Therapeutic Area: Oncology Product Name: SQ3370
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
